Your Name, date

Page 2 of 2

S. Lindsey Davis, M.D.

University of Colorado Cancer Center

University of Colorado Denver
Mail Stop 8117

12801 East 17th Avenue Room L18-8105

Aurora, Colorado 80045
Phone: (303)724-8681 Fax: 303-724-3889


Hematology and Oncology Fellowship, University of Colorado-Denver, Anschutz Medical Campus, Aurora, Colorado
Internal Medicine Residency, University of Colorado-Denver, Anschutz Medical Campus, Aurora, Colorado
Medical Degree, University of Missouri-Columbia School of Medicine, Columbia, Missouri
Bachelor of Science in Microbiology (Summa Cum Laude), University of Arkansas, Fayetteville, Arkansas / 2011-2014
Current Position
Assistant Professor
University of Colorado-Denver
Aurora, Colorado
Professional Experience
Chief Fellow
Division of Medical Oncology
University of Colorado-Denver, Anschutz Medical Campus
Aurora, Colorado
Chief Resident
Department of Internal Medicine
University of Colorado-Denver, Anschutz Medical Campus
Aurora, Colorado / 2014-Present

Certification and Licensure

Diplomate, American Board of Internal Medicine
Colorado State Medical License (active)
Drug Enforcement Agency License (active) / 2010

Professional Memberships and Activities

American Society of Clinical Oncology / 2012-Present

Honors and Awards

ASCO/AACR Methods in Clinical Cancer Research Workshop Participant
/ 2013

Committee Assignments and Administrative Services

Hematology/Oncology Fellowship Program Evaluation Committee
University of Colorado Hematology-Oncology Fellowship Selection Committee
Schwartz Center Rounds Planning Committee
Hematology/Oncology Fellowship Quality Improvement Project Leader
University of Colorado Internal Medicine Student Evaluation Committee
University of Colorado Internal Medicine Residency Selection Committee / 2014-Present

Educational Activities

Teaching Experience
Medical Student Core Curriculum Lecturer
Hematology and Oncology Grand Rounds Lecturer
Internal Medicine Grand Rounds Lecturer
Medical Student Board Review Lecturer
Medical Student Physical Exam Course, Small Group Leader
Medical Student Internal Medicine Lecture Series, Coordinator and Lecturer
Educational Course Participation
Practical Application of Molecular and Cell Biology Techniques for the Clinical
Investigator / 3/2014
3/2012, 3/2013, 1/2014


1.  Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Want T, Albadine R, Schultz L, Partin AW, Jimeno A, et al. “A pharmacodynaimc study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clinical Cancer Research. 2010; 16(11):3057-66.
2.  Davis SL and Jimeno A. “Metastatic Colorectal Cancer: Focus on Panitumumab.” Clinical Medicine Reviews in Oncology. 2010;2:109-121.
3.  Davis SL, Eckhardt SG, Messersmith WA, and Jimeno A. “The Development of Regorafenib and its Current and Potential Future Role in Cancer Therapy.” Drugs of Today. 2013; 49(2): 105-115.
4.  Pitts TM, Davis SL, Eckhardt SG, and Bradshaw-Pierce EL. “Targeting Nuclear Kinases in Cancer: Development of Cell Cycle Kinase Inhibitors.” Pharmacology and Therapeutics. 2013. Advance online publication http://
5.  Davis SL, Eckhardt SG, Tentler JJ, and Diamond JR. “Triple-Negative Breast Cancer: Bridging the Gap from Cancer Genomics to Predictive Biomarkers.” Therapeutic Advances in Medical Oncology. 2014. Advance online publication. DOI: 10.1177/1758834013519843.
Manuscripts Accepted for Publication
1.  Kessler E, Davis SL, Brittain P, Leong S, Eckhardt SG, and Lieu CH. “Targeted Therapies” American Cancer Society Textbook of Cancer
2.  Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Pitts TM, Gangolli E,Fabrey R, O’Connell SM, Vincent P, Eckhardt SG. “Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.” Molecular Cancer Therapeutics.
3.  Tocce K, Davis SL. “Hematologic Abnormalities” Contraception for the Medically Challenging Patient / 2010

Abstracts and Presentations


Local/Regional Meetings
Pre-Postatectomy Rapamycin in Men with Advanced Localized Prostate Cancer
University of Colorado Department of Medicine Research Day
National/International Meetings
A First-in-human Phase I Study of the Novel Cancer Stem Cell (CSC) Targeting Antibody OMP-52M51 (anti-Notch1) Administered Intravenously to Patients with Certain Advanced Solid Tumors
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics / 11/2008